In this article, we will discuss the 11 Blue Chip Stocks to Invest in at 52-Week Lows. For the first time since 2023, the S&P 500 was seen in the market correction territory, according to US Bank ...

Our latest round-up of biotech financings includes nine-figure rounds for Marea, Santa Ana Bio, and Opthea, with InduPro, Elion, and iOnctura also in on the action. Incubated by Third Rock ...

Eylea does not have any known drug interactions. However, it’s still important to talk with your doctor about all medications, supplements, and vitamins you use before starting treatment with Eylea.

Six years before the start of the COVID-19 pandemic, an Ebola outbreak in West Africa had people fearing the possibility of a ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

A research team of the Cluster at the Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

A natural antibacterial molecule shows clinical promise. Its unusual binding site is on an excellent target: ...

Only a month ago, Opthea was making preparations for the potential launch of a new eye disease drug onto the market. Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the ...

Investing.com -- Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell 1.5% following a U.S. appeals court decision that upheld a previous ruling, effectively denying a stay on ...

A mid-stage trial of 4D Molecular Therapeutics gene therapy for eye disease age-related macular degeneration (AMD) 4D-150 has shown promising signs of efficacy, plus a reduced need for injections ...